Clinical Trial Update: Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis [Phase 2]

View source ↗

Summary

Phase II study evaluating the combination of Rituximab and DepoCyte in patients with primary cerebral non-Hodgkin lymphoma and systemic diffuse large B-cell lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cns Lymphoma
• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Depocyte
• Rituximab (rituximab)

Snippet

Sponsor: Lymphoma Study Association | Conditions: Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED